ATXI | Avenue Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7100 - 1.7950
52 Week Range	1.6000 - 26.48
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	19,616
Average Volume	46,628
Shares Outstanding	2,053,920
Market Cap	3,532,742
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-06-27

Valuation
Profitability
Growth
Health
P/E Ratio	0.07
Forward P/E Ratio	N/A
EPS	24.78
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	3
Country	USA
Website	ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

ATXI's peers: ADIL, ADXN, APVO, ATHE, HOTH, REVB, NRBO, VRAX, PBLA, PALI, QNRX, CFRX, ALLR, CNSP, WINT, KRBP, BDRX, CANF, CKPT, CELZ, EPIX, FBIO, GOVX, MBRX, MEIP, PSTV, PTN, SNGX

*Chart delayed

Analyzing fundamentals for ATXI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ATXI Fundamentals page.

Watching at ATXI technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ATXI Technicals page.